| Literature DB >> 29778259 |
Anne C Spaulding1, Madeline G Adee2, Robert T Lawrence3, Jagpreet Chhatwal4, William von Oehsen5.
Abstract
An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing. While high prices for direct-acting antivirals discourage treatment, potential strategies exist to lower prices.Entities:
Keywords: HCV elimination; Hepatitis C; Incarceration; Jail; Medicaid; Prison
Mesh:
Substances:
Year: 2018 PMID: 29778259 DOI: 10.1016/j.idc.2018.02.014
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN: 0891-5520 Impact factor: 5.982